SQZ TAC AAV
Alternative Names: SQZ AACsLatest Information Update: 28 Jun 2024
At a glance
- Originator SQZ Biotech
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
- 25 Mar 2021 AskBio and SQZ Biotech ends their research collaboration for SQZ-TAC-AAV for many genetic diseases